Viridian Therapeutics is a biotechnology company that develops gene therapies for inherited diseases. The company's lead product candidate, VRDN-001, is a gene therapy for Friedreich's ataxia, a rare genetic disease that causes progressive damage to the nervous system. Viridian Therapeutics was founded in 2018 and is headquartered in Cambridge, Massachusetts.